These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27760335)

  • 1. Two Bugs a NOD Away from Improving Cancer Therapy Efficacy.
    Araya RE; Goldszmid RS
    Immunity; 2016 Oct; 45(4):714-716. PubMed ID: 27760335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gut microbiota and efficacy of cancer therapies].
    Vétizou M; Daillère R; Zitvogel L
    Biol Aujourdhui; 2017; 211(1):51-67. PubMed ID: 28682227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.
    Gori S; Inno A; Belluomini L; Bocus P; Bisoffi Z; Russo A; Arcaro G
    Crit Rev Oncol Hematol; 2019 Nov; 143():139-147. PubMed ID: 31634731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of bone mass by the gut microbiota is dependent on NOD1 and NOD2 signaling.
    Ohlsson C; Nigro G; Boneca IG; Bäckhed F; Sansonetti P; Sjögren K
    Cell Immunol; 2017 Jul; 317():55-58. PubMed ID: 28576260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hidden Effect of Nod2 in the Host/Microbiota Relationship.
    Daniel N; Chassaing B
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):424-425. PubMed ID: 32479755
    [No Abstract]   [Full Text] [Related]  

  • 6. Nod2 Deficiency Leads to a Specific and Transmissible Mucosa-associated Microbial Dysbiosis Which Is Independent of the Mucosal Barrier Defect.
    Al Nabhani Z; Lepage P; Mauny P; Montcuquet N; Roy M; Le Roux K; Dussaillant M; Berrebi D; Hugot JP; Barreau F
    J Crohns Colitis; 2016 Dec; 10(12):1428-1436. PubMed ID: 27147452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota: a key orchestrator of cancer therapy.
    Roy S; Trinchieri G
    Nat Rev Cancer; 2017 May; 17(5):271-285. PubMed ID: 28303904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
    Strober W; Asano N; Fuss I; Kitani A; Watanabe T
    Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer effects of the microbiome and its products.
    Zitvogel L; Daillère R; Roberti MP; Routy B; Kroemer G
    Nat Rev Microbiol; 2017 Aug; 15(8):465-478. PubMed ID: 28529325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota modulation of chemotherapy efficacy and toxicity.
    Alexander JL; Wilson ID; Teare J; Marchesi JR; Nicholson JK; Kinross JM
    Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):356-365. PubMed ID: 28270698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.
    Daillère R; Vétizou M; Waldschmitt N; Yamazaki T; Isnard C; Poirier-Colame V; Duong CPM; Flament C; Lepage P; Roberti MP; Routy B; Jacquelot N; Apetoh L; Becharef S; Rusakiewicz S; Langella P; Sokol H; Kroemer G; Enot D; Roux A; Eggermont A; Tartour E; Johannes L; Woerther PL; Chachaty E; Soria JC; Golden E; Formenti S; Plebanski M; Madondo M; Rosenstiel P; Raoult D; Cattoir V; Boneca IG; Chamaillard M; Zitvogel L
    Immunity; 2016 Oct; 45(4):931-943. PubMed ID: 27717798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nod2 is essential for temporal development of intestinal microbial communities.
    Rehman A; Sina C; Gavrilova O; Häsler R; Ott S; Baines JF; Schreiber S; Rosenstiel P
    Gut; 2011 Oct; 60(10):1354-62. PubMed ID: 21421666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysbiotic gut microbiome: A key element of Crohn's disease.
    Øyri SF; Műzes G; Sipos F
    Comp Immunol Microbiol Infect Dis; 2015 Dec; 43():36-49. PubMed ID: 26616659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T helper 17 cells get the NOD.
    Stetson DB; Medzhitov R
    Immunity; 2007 Oct; 27(4):546-8. PubMed ID: 17967409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway.
    Jakopin Ž
    J Med Chem; 2014 Aug; 57(16):6897-918. PubMed ID: 24707857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cIAP proteins: keystones in NOD receptor signal transduction.
    Reardon C; Mak TW
    Immunity; 2009 Jun; 30(6):755-6. PubMed ID: 19538923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria.
    Ji G; Zhao J; Si X; Song W
    Adv Drug Deliv Rev; 2024 Aug; 211():115345. PubMed ID: 38834140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human microbiota and effectiveness of cancer chemotherapy.
    Shvets YV; Lukianova NY; Chekhun VF
    Exp Oncol; 2020 Jun; 42(2):82-93. PubMed ID: 32602287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging pathogenic links between microbiota and the gut-lung axis.
    Budden KF; Gellatly SL; Wood DL; Cooper MA; Morrison M; Hugenholtz P; Hansbro PM
    Nat Rev Microbiol; 2017 Jan; 15(1):55-63. PubMed ID: 27694885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The microbiome and innate immunity.
    Thaiss CA; Zmora N; Levy M; Elinav E
    Nature; 2016 Jul; 535(7610):65-74. PubMed ID: 27383981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.